Meeting
2022 ASCO Annual Meeting
Efficacy of olanzapine, netupitant, and palonosetron in controlling nausea and vomiting associated with highly emetogenic chemotherapy in patients with breast cancer (OLNEPA).
Authors
Camilla Vieira de Reboucas
Faculdade de Medicina do ABC, Santo André, Brazil
Camilla Vieira de Reboucas , Rafaela de Brito Alves , Alayne Magalhaes Trindade Domingues Yamada , Thiago Vidal Brito , Auro Del Giglio , Felipe Melo Cruz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT04669132
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 12104)
DOI
10.1200/JCO.2022.40.16_suppl.12104
Abstract #
12104
Poster Bd #
349
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari
Poster
2019 Supportive Care in Oncology Symposium
Antiemetic efficacy of intravenous (IV) NEPA in patients with breast cancer (BC) receiving anthracycline/cyclophosphamide (AC) chemotherapy.
First Author: Lee S. Schwartzberg
Poster
2018 ASCO Annual Meeting
Efficacy of haloperidol versus olanzapine for control of chemotherapy induced nausea and vomiting.
First Author: Soniya Dulal
Poster
2014 ASCO Annual Meeting
Phase 3 trial of APF530 versus palonosetron (PALO) in preventing chemotherapy-induced nausea and vomiting (CINV): Efficacy in breast cancer patients (pts) receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy.
First Author: Ralph V. Boccia